OM1 Launches MS Registry for Use in Research, Trial Planning
OM1, a technology company focused on chronic conditions, announced that it has launched a multiple sclerosis (MS) registry to generate data that may ultimately be used to improve care and develop treatments for the disease.
The OM1 registry is being touted as the largest, most representative MS data registry available for analytics, licensing, and collaboration. Registries typically use observational study methods to collect data that can be used to measure certain outcomes for a particular disease or condition. They typically serve scientific, clinical, or policy purposes.
OM1’s continually updated registry is reported to have an enrollment of more than 20,000 patients, who are being prospectively followed by neurologists for clinical and lab data, including longitudinal outcomes, relapses, treatment responses, subtype data where applicable, and disability scores.
“The high availability and depth of the registry data enables healthcare stakeholders to answer important questions around natural history, disease progression, treatment response, and outcomes,” Richard Gliklich, MD, the company’s CEO, said in a press release.
For modeling, analytics, and other investigative purposes, scientists may also obtain data from another 460,000 MS patients in the company’s Real-World Data Cloud.
Through the registry, users to have access to deep clinical MS data, research-grade information, analytics-ready data, and longitudinal data (mean follow up at 5.5 years). These data, OM1 reported, are a source of unique insights into a patient’s journey, disease activity, treatment effectiveness, treatment patterns, care pathways, healthcare prescriber patterns, and others.
According to OM1, the registry can be used to plan better clinical trials; to better understand the treatment market as well as unmet needs, outcomes, and behavior; to find patients and explore subtypes; and to analyze causes of gaps in care, treatment, and diagnosis.
“Early diagnosis and effective treatment are the best way to reduce the damaging effects and to improve an MS patient’s quality of life,” Gliklich said
It is estimated that about 1 million people in the U.S. have MS.
OM1 uses big clinical data and artificial intelligence to better understand, compare, and predict patient outcomes. The company has a special focus on chronic diseases like MS.